Tirzepatide Maintenance Dose After Weight Loss: What the Data Supports

Most of what is written about tirzepatide covers getting to a dose. Far less covers what happens once the weight has come off, which is where the more consequential decision sits. There is a trial that speaks directly to it, and its answer is uncomfortable: stopping is not a neutral act.

This page covers what SURMOUNT-4 measured, what a maintenance dose is and is not, the lowest-dose question, and the practical shape of a step down for anyone determined to come off. For the escalation side see the tirzepatide dosage guide, and for the results curve tirzepatide before and after. This is research use information and none of it is medical advice.

The Trial That Answers This

SURMOUNT-4 was built for exactly this question. All 670 participants took tirzepatide for a 36 week lead-in, reaching a mean weight reduction of 20.9 percent. They were then randomised: half continued, half switched to placebo, for a further 52 weeks.

A 19.4 percentage point gap over 52 weeks is not a subtle finding. The mechanism is the plain reading of it: tirzepatide substitutes for an appetite signal rather than resetting one, so when it clears, appetite returns to roughly where it started while the lower resting energy expenditure of a smaller body does not automatically reverse.

Worth noticing that the continuing arm was still losing weight at week 88, which is the second finding in that table and gets less attention than the regain. The curve in SURMOUNT-1 had not fully levelled by week 72 either.

What a Maintenance Dose Actually Is

The term gets used loosely and it is worth being precise, because it means something different here than it does for many drugs.

There is no separate maintenance formulation and no officially designated maintenance dose for tirzepatide. The approved maintenance doses are 5mg, 10mg and 15mg: in other words, the same doses used to produce the loss. A maintenance phase is a decision about goals, not a change in the drug.

In practice people mean one of two things. Either continuing at the dose that produced the result, which is what SURMOUNT-4 tested and the only version with trial evidence behind it. Or reducing to a lower dose that holds weight steady without driving further loss, which is common clinical practice and has not been tested against continuing.

The Lowest Effective Dose Question

The obvious appeal of stepping down is cost and tolerability. A 5mg maintenance dose is a third of the drug of a 15mg one, and the gastrointestinal burden generally tracks dose.

What makes it a judgement call rather than an obvious win is that the evidence does not extend to it. SURMOUNT-4 compared continuing at the maximum tolerated dose against stopping entirely. It did not test 15mg against 5mg for maintenance, so there is no trial answer to how much dose reduction is compatible with holding a result.

What is known: 5mg alone produced a 15.0 percent mean reduction in SURMOUNT-1, so it is a dose with real effect rather than a token one. That makes a step down to 5mg plausible for maintenance in a way that stepping down to 2.5mg, which is a tolerability step rather than a treatment dose, is not.

How a Step Down Is Usually Structured

For anyone reducing rather than stopping, the shape that most reflects clinical practice:

1. Hold the result first. Reducing dose while still actively losing confuses two variables at once. Most approaches wait until weight has been stable for a month or two.
2. One step at a time. 15mg to 10mg, hold for at least four to eight weeks, then reassess before considering 10mg to 5mg. The four week figure comes from how long steady state takes at any given dose.
3. Measure waist as well as weight. Weight fluctuates with fluid; waist tracks the thing that actually matters and moves more slowly.
4. Treat a slow regain as information. A kilogram or two of drift is noise. A consistent upward trend over six to eight weeks is the signal that the lower dose is not holding.
5. Go back up if it does not hold. Returning to the previous step is an ordinary adjustment, not a failure.

If You Are Stopping Entirely

SURMOUNT-4 is the honest starting point: expect appetite to return. It does not happen the day after the last injection, because the half-life is around five days and the drug is substantially cleared only by around 25 days, so it returns gradually over the following month. That gradual onset is what makes it easy to miss until several kilograms have gone back on.

What plausibly reduces the regain, none of it tested as a stopping protocol:

• Protein and resistance training established beforehand. Lean mass is what holds resting energy expenditure up, and it is the single largest modifiable variable after the drug itself.
• Eating structure that does not depend on appetite suppression. Portion habits practised while appetite was suppressed are the things that remain when it is not. See what to eat on a GLP-1.
• A taper rather than a stop. Untested, but it converts an abrupt return of appetite into a gradual one, which is easier to respond to.
• Deciding in advance what triggers a restart. A specific number is more useful than an intention.

The Cost Arithmetic

The honest reason most people ask about maintenance dosing is cost, and it is worth stating rather than talking around. Indefinite treatment at a full dose is expensive at every route, and that is the real constraint for most people rather than tolerability.

A step down to 5mg cuts the drug cost proportionally, which is the main argument in its favour. Route matters more than dose, though: the spread between a cash-price branded carton and a research vial is larger than the spread between 15mg and 5mg. A larger vial bought once is cheaper per milligram than repeated small ones, which matters more on an indefinite protocol than on a 72 week one; PSPeptides carries the 60mg presentation and is the only vendor we track shipping outside the United States. The full comparison is in tirzepatide cost and where to buy tirzepatide, and the dose arithmetic for a reduced dose from an existing vial is in the tirzepatide dosage calculator.

Key Takeaways

• SURMOUNT-4 is the trial that addresses this: after a 36 week lead-in to 20.9 percent loss, continuing produced a further 5.5 percent while stopping produced 14.0 percent regain over 52 weeks.
• There is no separate maintenance formulation. The maintenance doses are the same 5mg, 10mg and 15mg.
• Continuing at the dose that produced the result is the only approach with trial evidence behind it.
• Stepping down to 5mg is plausible, since 5mg produced 15.0 percent on its own, but it has not been tested for maintenance.
• 2.5mg is a tolerability step, not a maintenance dose.
• After stopping, appetite returns over roughly a month rather than immediately, which is why regain is easy to miss early.
• Lean mass is the largest modifiable variable after the drug itself.

Frequently Asked Questions

What is the maintenance dose of tirzepatide after weight loss?

There is no separate maintenance dose. The approved doses are 5mg, 10mg and 15mg, the same ones used to produce the loss, so a maintenance phase is a decision about goals rather than a change of drug. The only approach with trial evidence is continuing at the dose that produced the result, which is what SURMOUNT-4 tested. Reducing to a lower dose that holds weight steady is common in practice but has not been compared against continuing.

What happens if you stop taking tirzepatide?

Appetite returns, and weight generally follows. In SURMOUNT-4, participants who reached a 20.9 percent reduction over a 36 week lead-in and then switched to placebo regained 14.0 percent of body weight over the next 52 weeks, while those who continued lost a further 5.5 percent. The return is gradual rather than immediate, because the half-life is around five days and the drug is substantially cleared only by roughly 25 days.

Can you take a lower dose of tirzepatide to maintain weight loss?

It is plausible and it is untested. SURMOUNT-4 compared continuing at the maximum tolerated dose against stopping entirely, not 15mg against 5mg. What is known is that 5mg alone produced a 15.0 percent mean reduction in SURMOUNT-1, so it is a dose with real effect rather than a token one. 2.5mg is a different case: it is a tolerability step rather than a treatment dose.

How do you step down a tirzepatide dose?

The shape that most reflects clinical practice is to wait until weight has been stable for a month or two first, then reduce one step at a time, holding each new dose for at least four to eight weeks before reassessing. Four weeks is the minimum because that is roughly how long steady state takes at any given dose. Track waist as well as weight, treat a consistent upward trend over six to eight weeks as the signal that the lower dose is not holding, and return to the previous step if so.

Do you have to take tirzepatide forever?

Not necessarily, but the trial data makes clear that stopping usually means substantial regain, so it should be a planned decision rather than a default. What plausibly reduces regain is having protein intake, resistance training and an eating structure established before stopping, since those are what hold resting energy expenditure up once appetite returns. None of that has been tested as a stopping protocol.

Why do you keep losing weight on tirzepatide after a year?

Because the curve has not finished. In SURMOUNT-1 the weight curve was still descending at around week 72 of a 72 week trial, and in SURMOUNT-4 the arm that continued past the 36 week lead-in lost a further 5.5 percent over the following year. Continued loss well past the first year is the expected pattern rather than an anomaly.